Nkarta (NKTX) Competitors

Zevra Therapeutics (NASDAQ:ZVRA) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.

Which has more risk & volatility, ZVRA or NKTX?

Zevra Therapeutics has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Does the media refer more to ZVRA or NKTX?

In the previous week, Nkarta had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 9 mentions for Nkarta and 6 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.39 beat Nkarta's score of 0.50 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ZVRA or NKTX?

Zevra Therapeutics presently has a consensus target price of $22.29, indicating a potential upside of 135.08%. Nkarta has a consensus target price of $14.33, indicating a potential upside of 648.48%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Nkarta	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13

Does the MarketBeat Community favor ZVRA or NKTX?

Nkarta received 27 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Zevra Therapeutics an outperform vote while only 76.74% of users gave Nkarta an outperform vote.

Company	Underperform	Outperform
Zevra Therapeutics	Outperform Votes 39 95.12%	Underperform Votes 2 4.88%
Nkarta	Outperform Votes 66 76.74%	Underperform Votes 20 23.26%

Which has higher earnings and valuation, ZVRA or NKTX?

Zevra Therapeutics has higher revenue and earnings than Nkarta. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$40.59M	12.77	-$46.05M	-$1.90	-4.99
Nkarta	N/A	N/A	-$117.50M	-$1.51	-1.27

Is ZVRA or NKTX more profitable?

Nkarta has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Nkarta's return on equity of -27.13% beat Zevra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	-342.63%	-159.54%	-51.50%
Nkarta	N/A	-27.13%	-21.67%

Do insiders and institutionals hold more shares of ZVRA or NKTX?

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nkarta beats Zevra Therapeutics on 12 of the 18 factors compared between the two stocks.